Medtronic Adds AI to Reveal LINQ Insertable Cardiac Monitors

Medtronic has added artificial intelligence (AI) to all Reveal LINQ insertable cardiac monitor (ICM) devices in the U.S., Austria, and New Zealand via a cloud-based update.
 
The company rolled out Reveal LINQ in 2014. Now, Reveal LINQ users have access to AccuRhythm AI algorithms that lower false alerts and boost information accuracy. AccuRhythm AI first earned U.S. Food and Drug Administration (FDA) clearance for LINQ II ICMs in June 2021 and in April 2023 for Reveal LINQ ICMs.
 
Medtronic said it expects adding the algorithms on the ICM will reduce false alerts for atrial fibrillation (AF) by 85% and pause. True alerts are expected to lower by 98.2% and 99.9%, respectively. This should save clinicals over 186 hours of false alert review annually for every 200 Reveal LINQ patients, so clinicians can focus on more critical patient activities.
 
The AI platform applies deep learning algorithms to ICM data going into the CareLink network to remove a high percentage of false AF and false pause episodes. The AI platform and initial algorithms were developed using Medtronic’s database of over a million ECG heart rhythm episodes.
 
AccuRhythm AI is automatically applied in the cloud and requires no action on the part of patients.
 
“This milestone is both a nod to the past as we celebrate the thousands of patients who have benefited from Reveal LINQ over the last decade, and a glimpse into the future as an example of how AI can effectively update an established technology overnight,” said Stacey Churchwell, VP and GM of Cardiovascular Diagnostics and Services within Medtronic’s Cardiac Rhythm Management business.